Hope for untreatable cancers.
Cellestia is a privately-owned clinical-stage biopharma led by an experienced
team of scientists, drug developers and business professionals.
Our patented drug, CB-103 along with its companion diagnostic, is a small molecule with an innovative mode of action targeting NOTCH-driven cancers, and providing hope for patients with no other treatment options.
